MedTrace Logo

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

NCT00128297 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2023-03-28

No results posted yet for this study

Summary

The study objective is to evaluate the differences, in terms of first occurrence of a skeletal event, in patients with breast cancer and symptomatic bone metastases, when pamidronate is administered during 2 years, or when it is administered during 6 months, followed by a six month rest period, and again a 6 month treatment period.

Conditions

Interventions

DRUG

Pamidronate

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Spanish Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Study Director · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

  • Study Director · Hospital Clínico Universitario de Valencia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-18
Primary Completion
2004-06-04
Completion
2004-06-04

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00128297 on ClinicalTrials.gov